Sign Up to like & get
recommendations!
1
Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.01281
Abstract: PURPOSE The prognosis of patients with early-stage unfavorable Hodgkin lymphoma remains unsatisfactory. We assessed the efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (BV-AVD) in previously untreated, early-stage unfavorable Hodgkin lymphoma (ClinicalTrials.gov…
read more here.
Keywords:
hodgkin lymphoma;
early stage;
stage unfavorable;
two cycles ... See more keywords